2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 104

The Usefulness of A NEW Musculoskeletal ULTRASOUND Scoring System of the Hands and Wrist Joints (US10) for Evaluation of EARLY Rheumatoid Arthritis Patients
Abstract Number: 2626

The Utility of the Patient Health Questionnaire-9 to Assess Suicide Risk in Patients with Systemic Sclerosis
Abstract Number: 1395

The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Abstract Number: 52

The Validity of the Diagnosis Inflammatory Arthritis in Primary Care
Abstract Number: 385

The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines
Abstract Number: 783

The Wnt Inhibitors DKK1 and SFRP1 Are Downregulated by Promoter Hypermethylation in Systemic Sclerosis
Abstract Number: 2337

Therapeutic Promotion of CD8 CTL by CpG Oligodeoxynucleotides (ODN) in an Induced Model of Lupus
Abstract Number: 1583

Therapist and Patient Perspectives On Exercise Adherence: Are We On the Same Page?
Abstract Number: 1404

There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE
Abstract Number: 181

Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Abstract Number: 1125

Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study
Abstract Number: 1305

Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry
Abstract Number: 612

Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies
Abstract Number: 1602

Tie2 Signalling Induces a Pro-Inflammatory and Pro-Angiogenic Phenotype in Differentiated Macrophages, Independently of Macrophage Polarization Conditions, and Contributes to Production of Cytokines Elevated in Early Rheumatoid Arthritis
Abstract Number: 2662

Tightening up: Musculoskeletal Ultrasound Could Further Individualise Treatment Decisions in Early Rheumatoid Arthritis Patients Treated by a Step-up DMARD Escalation Regimen

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].